Academic Journal
Προβολή σε EDS
Συνδεδεμένο Πλήρες Κείμενο

Effects of Sarpogrelate Versus Aspirin on Whole Blood Viscosity in Patients With Type 2 Diabetes and Peripheral Artery Disease.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Effects of Sarpogrelate Versus Aspirin on Whole Blood Viscosity in Patients With Type 2 Diabetes and Peripheral Artery Disease.
Συγγραφείς: Nari F; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea., Lee J; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea., Kim J; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea., Lim S; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Πηγή: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2026 Nov; Vol. 28 (11), pp. 10449-10458. Date of Electronic Publication: 2026 Aug 24.
Τύπος έκδοσης: Journal Article; Randomized Controlled Trial; Comparative Study
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE
Imprint Name(s): Original Publication: Oxford : Wiley-Blackwell, c1999-
Ιατρικοί όροι (MeSH): Diabetes Mellitus, Type 2*/complications , Diabetes Mellitus, Type 2*/blood , Diabetes Mellitus, Type 2*/drug therapy , Diabetes Mellitus, Type 2*/physiopathology , Succinates*/therapeutic use , Succinates*/adverse effects , Aspirin*/therapeutic use , Aspirin*/adverse effects , Blood Viscosity*/drug effects , Peripheral Arterial Disease*/drug therapy , Peripheral Arterial Disease*/complications , Peripheral Arterial Disease*/blood , Peripheral Arterial Disease*/physiopathology , Diabetic Angiopathies*/drug therapy , Diabetic Angiopathies*/blood , Platelet Aggregation Inhibitors*/therapeutic use, Humans ; Female ; Male ; Middle Aged ; Aged ; Treatment Outcome
Περίληψη: Background: Whole blood viscosity (WBV) is associated with impaired microvascular circulation and cardiovascular risk in patients with Type 2 diabetes mellitus (T2DM) and peripheral artery disease (PAD). This study investigated the efficacy and safety of sarpogrelate compared with aspirin on WBV in patients with T2DM and PAD.
Methods: This randomised, open-label clinical trial enrolled adults with T2DM and PAD. A total of 66 participants were randomised to aspirin (n = 33) or sarpogrelate (n = 33) for 24 weeks. The primary endpoint was change in diastolic WBV at a shear rate of 1 s-1 from baseline to week 24. Secondary endpoints included tissue oxygen delivery index, pain visual analogue scale (VAS) and cold sensation scores.
Results: After 24 weeks, diastolic WBV did not decrease significantly in both groups (sarpogrelate group: 31.91 ± 7.83 to 30.76 ± 7.08, mean change, -1.15 ± 9.25; p = 0.509; aspirin group: 33.32 ± 8.86 to 32.12 ± 9.60, mean change, -1.20 ± 8.36; p = 0.432). VAS scores improved significantly in both groups (mean change, -9.09 ± 18.09; p = 0.007 for sarpogrelate; -6.13 ± 16.47; p = 0.047 for aspirin), with no between-group difference. Cold sensation scores improved only in the sarpogrelate group (mean change, -0.21 ± 0.55; p = 0.033 vs. -0.23 ± 0.85; p = 0.147 for aspirin group), with no between-group difference.
Conclusion: In patients with T2DM and PAD, sarpogrelate did not significantly improve WBV compared with aspirin. VAS scores and cold sensation improved significantly within the sarpogrelate group with no between-group difference.
(© 2026 John Wiley & Sons Ltd.)
References: H. F. Lee, S. W. Chen, J. R. Liu, et al., “Major Adverse Cardiovascular and Limb Events in Patients With Diabetes and Concomitant Peripheral Artery Disease Treated With Sodium Glucose Cotransporter 2 Inhibitor Versus Dipeptidyl Peptidase‐4 Inhibitor,” Cardiovascular Diabetology 19, no. 1 (2020): 160.
J. D. Newman, C. B. Rockman, M. Kosiborod, et al., “Diabetes Mellitus Is a Coronary Heart Disease Risk Equivalent for Peripheral Vascular Disease,” American Heart Journal 184 (2017): 114–120.
S. Y. Rhee and Y. S. Kim, “Peripheral Arterial Disease in Patients With Type 2 Diabetes Mellitus,” Diabetes & Metabolism Journal 39, no. 4 (2015): 283–290.
G. Sloop, R. E. Holsworth, Jr., J. J. Weidman, and J. A. St Cyr, “The Role of Chronic Hyperviscosity in Vascular Disease,” Therapeutic Advances in Cardiovascular Disease 9, no. 1 (2015): 19–25.
E. I. Cekirdekci and B. Bugan, “Whole Blood Viscosity in Microvascular Angina and Coronary Artery Disease: Significance and Utility,” Revista Portuguesa de Cardiologia (English Edition) 39, no. 1 (2020): 17–23.
O. K. Baskurt and H. J. Meiselman, “Blood Rheology and Hemodynamics,” Seminars in Thrombosis and Hemostasis 50, no. 6 (2003): 902–915.
J. I. Mbah, P. T. Bwititi, P. Gyawali, E. U. Nwose, and P. Bwititi, “Blood Viscosity Changes in Diabetes Mellitus: A 20‐Year Bibliometric Review and Future Directions,” Cureus 16, no. 7 (2024): e64211.
E. Succurro, P. Vizza, F. Cicone, et al., “Elevated Whole Blood Viscosity Is Associated With an Impaired Insulin‐Stimulated Myocardial Glucose Metabolism,” Cardiovascular Diabetology 23, no. 1 (2024): 431.
Y. I. Cho, M. P. Mooney, and D. J. Cho, “Hemorheological Disorders in Diabetes Mellitus,” Journal of Diabetes Science and Technology 2, no. 6 (2008): 1130–1138.
I. Velcheva, P. Damianov, N. Antonova, Z. Stoyneva, S. Mantarova, and V. Dimitrova, “Hemorheology and Vascular Reactivity in Patients With Diabetes Mellitus Type 2,” Clinical Hemorheology and Microcirculation 49, no. 1–4 (2011): 505–511.
J. H. Park, S. W. Han, and H.‐J. Yu, “The Good Genotype for Clopidogrel Metabolism Is Associated With Decreased Blood Viscosity in Clopidogrel‐Treated Ischemic Stroke Patients,” Journal of Neurocritical Care 13, no. 2 (2020): 93–100.
R. S. Rosenson, Q. Chen, S. D. Najera, P. Krishnan, M. L. Lee, and D. J. Cho, “Ticagrelor Improves Blood Viscosity‐Dependent Microcirculatory Flow in Patients With Lower Extremity Arterial Disease: The Hema‐Kinesis Clinical Trial,” Cardiovascular Diabetology 18, no. 1 (2019): 77.
K. Salhiyyah, E. Senanayake, M. Abdel‐Hadi, A. Booth, and J. A. Michaels, “Pentoxifylline for Intermittent Claudication,” Cochrane Database of Systematic Reviews, 2012, 1.
C. H. Lee, K. H. Jung, D. J. Cho, and S. K. Jeong, “Effect of Warfarin Versus Aspirin on Blood Viscosity in Cardioembolic Stroke With Atrial Fibrillation: A Prospective Clinical Trial,” BMC Neurology 19, no. 1 (2019): 82.
K. Tamura, T. Kanzaki, Y. Saito, M. Otabe, Y. Saito, and N. Morisaki, “Serotonin (5‐Hydroxytryptamine, 5‐HT) Enhances Migration of Rat Aortic Smooth Muscle Cells Through 5‐HT2 Receptors,” Atherosclerosis 132, no. 2 (1997): 139–143.
K. Vikenes, M. Farstad, and J. E. Nordrehaug, “Serotonin Is Associated With Coronary Artery Disease and Cardiac Events,” Circulation 100, no. 5 (1999): 483–489.
Y. Ahn, J. Jang, S. Bu, N. Aung, H.‐S. Ahn, and K.‐S. Yum, “Study Design and Rationale of a Randomized Trial Comparing Aspirin–Sarpogrelate Combination Therapy With Aspirin Monotherapy: Effects on Blood Viscosity and Microcirculation in Cardiovascular Patients,” Diagnostics 15, no. 11 (2025): 1373.
T. Yamashita, K. Kitamori, M. Hashimoto, S. Watanabe, J. Giddings, and J. J. Yamamoto, “Conjunctive Effects of the 5HT2 Receptor Antagonist, Sarpogrelate, on Thrombolysis With Modified Tissue Plasminogen Activator in Different Laser‐Induced Thrombosis Models,” Pathophysiology of Haemostasis and Thrombosis 30, no. 6 (2000): 321–332.
S. Uchiyama, Y. Ozaki, K. Satoh, K. Kondo, and K. Nishimaru, “Effect of Sarpogrelate, a 5‐HT2A Antagonist, on Platelet Aggregation in Patients With Ischemic Stroke: Clinical‐Pharmacological Dose‐Response Study,” Cerebrovascular Diseases 24, no. 2–3 (2007): 264–270.
K. S. Yum, S. G. Kang, J. W. Lee, and Y. I. Cho, “Effects of Sarpogrelate on Blood Viscosity,” Microvascular Research 145 (2023): 104439.
Y. Li, X.‐x. Tian, T. Liu, and R.‐t. Wang, “Association Between Whole Blood Viscosity and Arterial Stiffness in Patients With Type 2 Diabetes Mellitus,” Endocrine 49, no. 1 (2015): 148–154.
B. Sandhagen and L. Lind, “Whole Blood Viscosity and Erythrocyte Deformability Are Related to Endothelium‐Dependent Vasodilation and Coronary Risk in the Elderly,” Clinical Hemorheology and Microcirculation 50, no. 4 (2012): 301–311.
A. Bowers, D. Pepple, and H. Reid, “Optimal Haematocrit in Subjects With Normal Haemoglobin Genotype (HbAA), Sickle Cell Trait (HbAS), and Homozygous Sickle Cell Disease (HbSS),” Clinical Hemorheology and Microcirculation 47, no. 4 (2011): 253–260.
J.‐E. Yi and H.‐J. Youn, “Hemorheological Abnormalities and Their Associations With Coronary Blood Flow in Patients With Cardiac Syndrome X: A Comparison Between Males and Females,” Perfusion 32, no. 1 (2017): 57–67.
R. S. Rosenson, “Treatment With Aspirin and Dipyridamole Is More Effective Than Aspirin in Reducing Low Shear Blood Viscosity,” Microcirculation 15, no. 7 (2008): 615–620.
S. Ren, S. Qian, W. Wang, J. Liu, and P. Liu, “Prospective Study of Sarpogrelate Hydrochloride on Patients With Arterioscler Osis Obliterans,” Annals of Thoracic and Cardiovascular Surgery 19, no. 1 (2013): 30–34.
H. Matsuo and H. Shigematsu, “Effects of the 5‐HT2A Antagonist Sarpogrelate on Walking Ability in Patients With Intermittent Claudication as Measured Using the Walking Impairment Questionnaire,” Annals of Vascular Diseases 1, no. 2 (2008): 102–110.
H. K. Saini, N. Takeda, R. K. Goyal, H. Kumamoto, A. S. Arneja, and N. S. Dhalla, “Therapeutic Potentials of Sarpogrelate in Cardiovascular Disease,” Cardiovascular Drug Reviews 22, no. 1 (2004): 27–54.
Y. Su, N. Mao, M. Li, et al., “Sarpogrelate Inhibits the Expression of ICAM‐1 and Monocyte–Endothelial Adhesion Induced by High Glucose in Human Endothelial Cells,” Molecular and Cellular Biochemistry 373, no. 1 (2013): 195–199.
H. Yamaguchi, “Effects of Sarpogrelate Hydrochloride (MCI‐9042) on Platelet Aggregation, Red Blood Cell Deformability and Blood Viscosity in the Treatment of Patients With Arteriosclerosis Obliterans,” Rinsho Iyaku 7 (1991): 1235–1241.
R. Rosenson, D. Wolff, D. Green, A. H. Boss, and K. R. Kensey, “Aspirin,” Journal of Thrombosis and Haemostasis 2, no. 2 (2004): 335–341.
N. Hotta, J. Nakamura, Y. Sumita, et al., “Effects of the 5‐HT2A Receptor Antagonist Sarpogrelate in Diabetic Patients With Complications,” Clinical Drug Investigation 18, no. 3 (1999): 199–207.
H. Hashizume, M. Kawakami, M. Yoshida, M. Okada, Y. Enyo, and Y. Inomata, “Sarpogrelate Hydrochloride, a 5‐HT2A Receptor Antagonist, Attenuates Neurogenic Pain Induced by Nucleus Pulposus in Rats,” Spine 32, no. 3 (2007): 315–320.
E. S. Lee, M. Y. Lee, M.‐H. Kwon, et al., “Sarpogrelate Hydrochloride Ameliorates Diabetic Nephropathy Associated With Inhibition of Macrophage Activity and Inflammatory Reaction in Db/Db Mice,” PLoS One 12, no. 6 (2017): e0179221.
L. Cao, L. Ding, Q. Xia, et al., “Macrophage Polarization in Diabetic Vascular Complications: Mechanistic Insights and Therapeutic Targets,” Journal of Translational Medicine 23, no. 1 (2025): 1050.
J. Yamakawa, T. Takahashi, S. Saegusa, et al., “Effect of the Serotonin Blocker Sarpogrelate on Circulating Interleukin‐18 Levels in Patients With Diabetes and Arteriosclerosis Obliterans,” Journal of International Medical Research 32, no. 2 (2004): 166–169.
M. M. McDermott, P. Greenland, K. Liu, et al., “Leg Symptoms in Peripheral Arterial Disease: Associated Clinical Characteristics and Functional Impairment,” Journal of the American Medical Association 286, no. 13 (2001): 1599–1606.
J. Spertus, P. Jones, S. Poler, and K. Rocha‐Singh, “The Peripheral Artery Questionnaire: A New Disease‐Specific Health Status Measure for Patients With Peripheral Arterial Disease,” American Heart Journal 147, no. 2 (2004): 301–308.
H. G. Je, B. H. Kim, K. I. Cho, J. S. Jang, Y. H. Park, and J. Spertus, “Correlation Between Patient‐Reported Symptoms and Ankle‐Brachial Index After Revascularization for Peripheral Arterial Disease,” International Journal of Molecular Sciences 16, no. 5 (2015): 11355–11368.
Grant Information: Daewoong Pharmaceutical Company
Contributed Indexing: Keywords: 5‐HT2A receptor; aspirin; peripheral artery disease; sarpogrelate; type 2 diabetes mellitus; whole blood viscosity
Substance Nomenclature: 19P708E787 (sarpogrelate)
0 (Succinates)
R16CO5Y76E (Aspirin)
0 (Platelet Aggregation Inhibitors)
Entry Date(s): Date Created: 20260825 Date Completed: 20261008 Latest Revision: 20261013
Update Code: 20261014
DOI: 10.1111/dom.71265
PMID: 42638218
Βάση Δεδομένων: MEDLINE
Περιγραφή
ISSN:1463-1326
DOI:10.1111/dom.71265